158 related articles for article (PubMed ID: 10550269)
1. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study.
Shoab SS; Scurr JH; Coleridge-Smith PD
Eur J Vasc Endovasc Surg; 1999 Oct; 18(4):334-8. PubMed ID: 10550269
[TBL] [Abstract][Full Text] [Related]
2. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study.
Shoab SS; Porter J; Scurr JH; Coleridge-Smith PD
Eur J Vasc Endovasc Surg; 1999 Apr; 17(4):313-8. PubMed ID: 10204053
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma vascular endothelial growth factor among patients with chronic venous disease.
Shoab SS; Scurr JH; Coleridge-Smith PD
J Vasc Surg; 1998 Sep; 28(3):535-40. PubMed ID: 9737465
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study.
Shoab SS; Porter JB; Scurr JH; Coleridge-Smith PD
J Vasc Surg; 2000 Mar; 31(3):456-61. PubMed ID: 10709057
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
Danielsson G; Jungbeck C; Peterson K; Norgren L
Eur J Vasc Endovasc Surg; 2002 Jan; 23(1):73-6. PubMed ID: 11748952
[TBL] [Abstract][Full Text] [Related]
7. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
[TBL] [Abstract][Full Text] [Related]
8. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms.
Smith PD
Microcirculation; 2000; 7(6 Pt 2):S35-40. PubMed ID: 11151970
[TBL] [Abstract][Full Text] [Related]
9. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
Lyseng-Williamson KA; Perry CM
Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
[TBL] [Abstract][Full Text] [Related]
10. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
12. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
13. From symptoms to leg edema: efficacy of Daflon 500 mg.
Nicolaides AN
Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
[TBL] [Abstract][Full Text] [Related]
15. [Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma].
Zhao J; Hu J; Cai J
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):389-92. PubMed ID: 11810769
[TBL] [Abstract][Full Text] [Related]
16. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy.
Murphy MA; Joyce WP; Condron C; Bouchier-Hayes D
Eur J Vasc Endovasc Surg; 2002 Apr; 23(4):349-52. PubMed ID: 11991698
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.
Duque JL; Loughlin KR; Adam RM; Kantoff PW; Zurakowski D; Freeman MR
Urology; 1999 Sep; 54(3):523-7. PubMed ID: 10475365
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Zhao J; Hu J; Cai J; Yang X; Yang Z
Chin Med J (Engl); 2003 May; 116(5):772-6. PubMed ID: 12875699
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer.
Wallner G; Ciechański A; Dabrowski A; Kozłowski M; Roliński J; Laudański J; Cwik G
Folia Histochem Cytobiol; 2001; 39 Suppl 2():122-3. PubMed ID: 11820569
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
